




SCYNEXIS, Inc.
Investor Relations Department
3501 C Tricenter Boulevard
Durham, NC 27713
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: SCYX

| | |
|---------------|---|
| Last Trade: | 1.62 |
| Trade Time: | 4:00 PM ET May 23, 2017 |
| Change: | 0.03  (+1.887%) |
| Day Range | 1.57 - 1.62 |
| 52-Week Range | 1.55 - 5.51 |
| Volume | 142,914 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

SCYNEXIS, Inc. is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapeutic areas.

We are developing our lead product candidate, SCY-078, as a novel and structurally distinct triterpenoid glucan synthase inhibitor. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 11, 2017

[Potent in vitro Activity of SCYNEXIS' SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention \(CDC\)](#)

May 8, 2017

[SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status](#)

Apr 25, 2017

[Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS' Lead Anti-infective Candidate SCY-078](#)

Apr 21, 2017

[SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID](#)

Apr 12, 2017

[SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases \(ECCMID\)](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Apr 26, 2017

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)